|1.||Wedel, M K: 4 articles (05/2006 - 11/2004)|
|2.||Yu, Rosie Z: 3 articles (02/2007 - 02/2003)|
|3.||Baker, B F: 3 articles (05/2006 - 05/2006)|
|4.||Miner, P B: 3 articles (05/2006 - 05/2006)|
|5.||Xia, S: 3 articles (05/2006 - 05/2006)|
|6.||Levin, Arthur A: 3 articles (01/2006 - 02/2003)|
|7.||Yacyshyn, B R: 3 articles (07/2005 - 07/2002)|
|8.||Prous, J R: 2 articles (12/2006 - 06/2005)|
|9.||Rabasseda, X: 2 articles (12/2006 - 06/2005)|
|10.||Chuang, E: 2 articles (05/2006 - 05/2006)|
|1.||Crohn Disease (Crohn's Disease)
07/01/2005 - "Although the overall clinical trial was negative, we have identified a trend towards clinical remission with Alicaforsen therapy in a subgroup of patients with Crohn's disease expressing ASCA(+)/pANCA(-). "
05/01/2001 - "The aim of this study was to investigate safety and efficacy of ISIS-2302 in chronic active Crohn's disease (CACD). "
09/01/1999 - "A 300-patient, pivotal quality trial investigating the steroid-sparing and remission-inducing qualities of ISIS 2302 in patients with steroid-dependent Crohn's disease is completely enrolled, with results expected in the first half of 2000. "
06/01/1998 - "The aim of this study was to obtain preliminary assessment of tolerability, pharmacology, and efficacy of ISIS 2302 in Crohn's disease. "
02/01/2005 - "Trials with the anti-ICAM-1 antisense oligonucleotide ISIS-2302 in steroid refractory Crohn's disease have provided conflicting efficacy data. "
08/01/2013 - "Meta-analysis using individual patient data: efficacy and durability of topical alicaforsen for the treatment of active ulcerative colitis."
05/15/2006 - "METHODS An open-label study was conducted to assess the relative absorption (local and systemic pharmacokinetics) and pharmacologic activity of alicaforsen enema in subjects with active ulcerative colitis. "
05/15/2006 - "A phase II dose ranging, double-blind, placebo-controlled study of alicaforsen enema in subjects with acute exacerbation of mild to moderate left-sided ulcerative colitis."
11/01/2004 - "A randomised, controlled, double blind, escalating dose study of alicaforsen enema in active ulcerative colitis."
05/15/2006 - "To determine the systemic and local bioavailability of alicaforsen, and its activity when administered as a once daily enema in subjects with active ulcerative colitis. "
02/01/2004 - "In an open-label, uncontrolled study, 12 patients with chronic, unremitting pouchitis were treated with 240 mg alicaforsen antisense enema nightly for 6 weeks. "
02/01/2004 - "An enema formulation of alicaforsen, an antisense inhibitor of intercellular adhesion molecule-1, in the treatment of chronic, unremitting pouchitis."
05/15/2006 - "Alicaforsen is an antisense oligonucleotide inhibitor of intercellular adhesion molecule 1 protein expression with activity in subjects with ulcerative colitis and pouchitis. "
07/01/2004 - "Making sense of antisense: ISIS 2302 (alicaforsen) in the treatment of pouchitis. "
05/15/2006 - "Alicaforsen is an antisense oligonucleotide designed to inhibit expression of human intercellular adhesion molecule 1. Previous clinical studies have demonstrated activity of alicaforsen enema in ulcerative colitis and pouchitis. "
|5.||Psoriasis (Pustulosis Palmaris et Plantaris)
|1.||Intercellular Adhesion Molecule-1 (Intercellular Adhesion Molecule 1)
|4.||Messenger RNA (mRNA)
|5.||Carrier Proteins (Binding Protein)